Clinical Trial

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Study acronym: REIMAGINE 5
Completed Phase 3
View on ClinicalTrials.gov →
Summary
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
Protocol Amendment History 1 change
critical Trial completed 2026-07-19
Trial Details
NCT Number NCT06534411
Lead Sponsor Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 2
Enrollment 1,023 participants
Start Date 2024-11-05
Primary Completion 2026-06-02 (estimated)
Study Completion 2026-07-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-17